Raltitrexed
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00293 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | sclerosing cholangitis | KG + DL |
| 2 | myelodysplastic syndrome | KG + DL |
| 3 | sickle cell-hemoglobin d disease syndrome | KG + DL |
| 4 | sickle cell-beta-thalassemia disease syndrome | KG + DL |
| 5 | sickle cell-hemoglobin c disease syndrome | KG + DL |
| 6 | hereditary persistence of fetal hemoglobin-sickle cell disease syndrome | KG + DL |
| 7 | sickle cell-hemoglobin E disease syndrome | KG + DL |
| 8 | unclassified myelodysplastic syndrome | KG + DL |
| 9 | refractory cytopenia of childhood | KG + DL |
| 10 | partial deletion of the long arm of chromosome 5 | KG + DL |
| 11 | aregenerative anemia | KG + DL |
| 12 | severe congenital hypochromic anemia with ringed sideroblasts | KG + DL |
| 13 | hyperthyroidism | KG + DL |
| 14 | plasma cell myeloma | KG + DL |
| 15 | resistance to thyroid hormone due to a mutation in thyroid hormone receptor beta | KG + DL |
| 16 | autosomal dominant familial hematuria-retinal arteriolar tortuosity-contractures syndrome | KG + DL |
| 17 | indolent plasma cell myeloma | KG + DL |
| 18 | brain small vessel disease 1 with or without ocular anomalies | KG + DL |
| 19 | diabetic nephropathy | KG + DL |
| 20 | hyperthyroxinemia | KG + DL |
| 21 | malignant pleural mesothelioma | KG + DL |
| 22 | refractory hematologic cancer | KG + DL |
| 23 | sickle cell disease and related diseases | KG + DL |
| 24 | urinary bladder cancer | KG + DL |
| 25 | ureteric orifice cancer | KG + DL |
| 26 | gastric linitis plastica | KG + DL |
| 27 | urinary system neoplasm | KG + DL |
| 28 | myeloid leukemia | KG + DL |
| 29 | urinary bladder neoplasm | KG + DL |
| 30 | conjunctivitis | KG + DL |
| 31 | gestational trophoblastic neoplasm | KG + DL |
| 32 | bladder urothelial papilloma | KG + DL |
| 33 | myeloid/lymphoid neoplasms associated with eosinophilia and abnormality of PDGFRA, PDGFRB, FGFR1 or JAK2 | KG + DL |
| 34 | bladder squamous papilloma | KG + DL |
| 35 | conjunctivitis (disease) | KG + DL |
| 36 | gastric carcinoma | KG + DL |
| 37 | malignant epithelioid mesothelioma | KG + DL |
| 38 | common wart | KG + DL |
| 39 | urinary bladder carcinoma | KG + DL |
| 40 | sarcomatoid mesothelioma | KG + DL |
| 41 | medullary cystic kidney disease | KG + DL |
| 42 | bladder leiomyoma | KG + DL |
| 43 | bone Paget disease | KG + DL |
| 44 | malignant visceral pleura tumor | KG + DL |
| 45 | bladder urachal adenocarcinoma | KG + DL |
| 46 | colonic neoplasm | KG + DL |
| 47 | gestational uterine corpus choriocarcinoma | KG + DL |
| 48 | hydatidiform mole, recurrent | KG + DL |
| 49 | acute lymphoblastic leukemia (disease) | KG + DL |
| 50 | partial hydatidiform mole | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.